In late 2019, a pneumonia-like disease later known as SARS-CoV-2 was found in Wuhan, China. This disease was transmitted via droplets and spread rapidly worldwide. SARS-CoV-2 binds to ACE-2 receptors in the lungs, triggering pneumonia and both local and systemic inflammation. On some occasions, COVID-19 patients may suffer complications such as myocarditis due to systemic inflammatory effects or direct invasion of ACE-2-receptor expressing heart cells. Underlying cardiovascular diseases may also be exacerbated by the presence of COVID-19-induced myocarditis, thus increasing morbidity and mortality rate. Early biomarkers may include an elevated troponin level, later manifested as an acute coronary syndrome or other cardiac disease. Until now, there was no definitive treatment for COVID-19-induced myocarditis. Therefore, early recognition and supportive care may improve patients' conditions and decrease the mortality rate.
Key words: Myocarditis, COVID-19, Pathophysiology, Diagnostic, Treatment
|
